bureau of: Santen Pharmaceutical, Mitsubishi Tanabe Pharma, Pfizer, Abbott ... ProScribe â part of the Envision Pharma Group, and were funded by Eli Lilly and ...
!"#$%&'"()$*+,'%&'-..$%/+%0+12'3*23'"4+5%$/2+6"7"&-+ $/+,"2$-/2.+8$2)+9*2$:-+,.%'$"2$*+9'2)'$2$.+;'-"2-#+8$2)+$?37"@ A:-'+BC+8-->. 6D.$'D- :"/+#-'+E-$F#-GH I"."2%+A>"#"GC J)$/+K--GL J"2)-'$/-+KM+1)34-'GL 13*)$2'$2"+!"2)7"//GL J)-/NO-/+K$/GL 6":$#+97"2%GL+,)$4$(+5M+I-".-P
HK-$#-/+Q/$:-'.$2R+I-#$*"4+J-/2'-G+K-$#-/G+;)-+S-2)-'4"/#.T+C12M+K3>-U.+
$$%,
!
577$2-@5&23, ! d;-@5&23-$:5,&52-52-.*28-5:-1553#0:*4,-eH-*-Q0:$*63&9$-?:53$&26526$23:*3&52-f_-)/ZT-*3,6:$$2&2/ C V5&23-$:5,&52,->$:$-*,,$,,$8+4-6$23:*7-:$*8&2/ ! =63&9$-?,5:&*3&6-,%&2-7$,&52-5:-*856()$23$8-.&,35:4-51-?7*P($?,5:&*,&,
V=*43.$%/ J'$2-'$" ! Q(::$23-5:-?:&5:-(,$-51+&575/&6-*/$23,-15:-3:$*3)$2351-?,5:&*,&,-5:-?,5:&*3&6*:3.:&3&, ! "2*8$P(*3$-:$,?52,$-35-dB6RO=HR, ! Q(::$23-(,$-b*3-,3(84-$23:4c-51f;-6RO=HR ! F$:&5(,-&21$63&52->&3.&2I-)523.,-?:&5:-35:*285)&'*3&52
! S#3$2,&52-?$:&58-?5?(7*3&52C =77-?*3&$23,->.5-$23$:$8-3.$-$#3$2,&52-?$:&58-*28-:$6$&9$8-d;-85,$51-,3(84-)$8&6*3&52-8(:&2/-3.&,-?$:&58 ! G:$,?$6&1&$8 *2*74,&, C )DFF 8*3*->$:$-$#67(8$8-&1-3.$-:*8&5/:*?.->*,-3*%$2-*13$:-3.$,6.$8(7$8-9&,&3-8*3$ o G:$,$23$8-*,-)$*2-6.*2/$-1:5)-+*,$7&2$-35-h$$%-EA! G5,3-.56-*2*74,&, C )DFF 8*3*-1:5)-:*8&5/:*?.,-3*%$2-*13$:-3.$-,6.$8(7$8-9&,&3-8*3$>$:$-&23$:?57*3$8 o G:$,$23$8-*,-)$*2-6.*2/$-1:5)-+*,$7&2$-35-h$$%-EAC Q()(7*3&9$-?:5+*+&7&34-?753,->$:$-6:$*3$8-35-9&,(*7&'$-?*3&$2307$9$78*3* C F())*:&$,-*:$-?:$,$23$8-15:-3.$-?:5?5:3&52-51-?*3&$23,->&3.-25:*8&5/:*?.&6-?:5/:$,,&52J-8$1&2$8-*,-3.$-)DFF 6.*2/$-1:5)+*,$7&2$-35-h$$%-EA-p-6(30511-9*7($,-51K-^\^J-^\EJ-*28-;\IA-b3.$,)*77$,3-8$3$63*+7$-6.*2/$-1:5)-+*,$7&2$-35-h$$%-EA-&2-3.&,-,3(84c ! O&,,&2/-8*3*->$:$-&)?(3$8-(,&2/-7&2$*:-$#3:*?57*3&52-)$3.58-&1-d;?5,3+*,$7&2$ 9*7($->*,-*9*&7*+7$ (56678'$"9*1":*0;9* (390%0*9"532'&"6-'1 ? ()* + " ! @ -
:; < (= # ? ()* + " ! $ -
& ' ( )*+ , -. / 0 -12 3 / / 4
& ' ( )*+ , -. $ 0 -12 3 / 5 4
7 8 7 )*+ , -. $ 0 -12 3 % / 4
8 9 8 )*+ , -. / 0 -12 3 / 7 4
8 9 8 )*+ , -. $ 0 -12 3 / 5 4
*+ , -. / 0 )*+ , -. / 0 -1 2 3 6 # 4
*+ , -. $ 0 )*+ , -. $ 0 -1 2 3 6 # 4
*+ , -. / 0 )*+ , -. / 0 -1 2 3 6 7 4
*+ , -. $ 0 )*+ , -. $ 0 -1 2 3 6 : 4
%
$
"
#
!"
;B\$$%,Y-"DDj"23$230350D:$*3Y-)DFFj9*2-8$:-n$&@8$ )58&1&$8-D53*7-F.*:?-F65:$Y-WH"j2520:$,?528$:-&)?(3*3&52YGNej?7*6$+5Y-FRj,3*28*:8-8$9&*3&52
!"#$%&'()"#"*+)',%&-+$.)./0'(.#1%&%#*%'2 34567'8++#+9+)"7':;7'?'@+#A+&0'53B5C7'3456?'D&%E".AF)0'9&%F%#$%G'+$'HJ'345C
&(
&"
;B\I^\^`
,%.2+)%*+7;11G+ /+aje
$:$-&23$:?57*3$8Y-+ ;\IA-6(30511-+*,$8-523.$-FRQ-1:5)-+*,$7&2$-35-h$$%-EA-&2-3.&,-,3(84"gS-iAhja^-&#$%&'()*+ $9$:4-A->$$%,Y-"gS-iBhja^-)/-&#$%&'()*+ $9$:4-B->$$%,Y-)DFFj9*2-8$:-n$&@8$ )58&1&$8D53*7-F.*:?-F65:$Y-W#j2()+$:-51-?*3&$23,->&3.-2520)&,,&2/-6.*2/$-1:5)-+*,$7&2$-8*3*Y-FRQj,)*77$,3-8$3$63*+7$-6.*2/$*
B^-baa\`c
&""
,%.2+)%*+7;11G+ /+aje
969X $$%,
6$.*4%.3'-. !
! "
B;-b`I\Ac
*-G5,3-.56-*2*74,&,K-8*3*-1:5)-:*8&5/:*?.,-3*%$2-*13$:-3.$-,6.$8(7$8-9&,&3-8*3$->$:$-&23$:?57*3$8Y-+-;\IA-6(30511-+*,$8-523.$-FRQ-1:5)-+*,$7&2$-35-h$$%-EA-&2-3.&,-,3(84Y-=R=jB^-)/-*8*7&)()*+-$9$:4-A->$$%,-b*63&9$-:$1$:$26$-*:)cY-"gSiAhja^-&#$%&'()*+ $9$:4-A->$$%,Y-"gS-iBhja^-)/-&#$%&'()*+ $9$:4-B->$$%,Y-)DFFj9*2-8$:-n$&@8$ )58&1&$8-D53*7F.*:?-F65:$Y-W#j2()+$:-51-?*3&$23,->&3.-2520)&,,&2/-6.*2/$-1:5)-+*,$7&2$-8*3*Y-FRQj,)*77$,3-8$3$63*+7$-6.*2/$-
(
!"
%"
&"
!"
;B\$$%,Y-)DFFj9*2-8$:-n$&@8$ )58&1&$8-D53*7-F.*:?-F65:$Y-W#j2()+$:-51-?*3&$23,->&3.-2520)&,,&2/-6.*2/$-1:5)-+*,$7&2$8*3*Y-GNej?7*6$+5Y-FRQj,)*77$,3-8$3$63*+7$-6.*2/$-
J%/2$/3%3.+$?37"@ m'%3(.\+7;11 +BC+J3734"2$:-+,'%@"@$4$2R+,4%2G+ K$/-"'+V=2'"(%4"2$%/G" V=2-/.$%/+,-'$%#+,%(34"2$%/++
!"
&(
,%.2+)%*+7;11G+ /+aje
*
! D.$-)DFF 6.*2/$-1:5)-+*,$7&2$-35-h$$%-EA->*,-)&2&)*7-15:-*77/:5(?,-b?:$,?$6&1&$8 *28-?5,3-.56-*2*74,&,c ,'-.(-*$0$-#+9/"4R.$." b8*3*-*13$:-9&,&3-$#67(8$8c
) * + ,-. / 01 # 2 034 5 6 # ( 708 6 # # 9 ) * + ,-. / 01 ! 2 034 5 6 # $ 708 6 # ( 9
!"
`\_-b_\Ac
R*3*-*:$-)$*2-b,3*28*:8-8$9&*3&52c-(27$,,-,3*3$8-53.$:>&,$ =R=jB^-)/-*8*7&)()*+-$9$:4-A->$$%,-b*63&9$-:$1$:$26$-*:)cY-NO"j+584-)*,,-&28$#Y-6RO=HRj6529$23&52*7-8&,$*,$0 )58&14&2/-*23&:.$()*3&6 8:(/Y-QHGjQ0:$*63&9$-?:53$&2Y-n=i0R"jn$*73.-=,,$,,)$23-i($,3&522*&:$0R&,*+&7&34-"28$#Y-"gSiAhja^-&#$%&'()*+ $9$:4-A->$$%,Y-"gS-iBhja^-)/-&#$%&'()*+ $9$:4-B->$$%,Y-)DFFj9*2-8$:-n$&@8$ )58&1&$8-D53*7F.*:?-F65:$Y-W#j2()+$:-51-?*3&$23,->&3.-252)&,,&2/ 9*7($,Y-GNej?7*6$+5Y-G,=j?,5:&*3&6-*:3.:&3&,-
AI\_^\B;
n
!"
_\A-b_\Ec-----------$$%,Y-"gS-iBhja^-)/&#$%&'()*+ $9$:4-B->$$%,Y-)DFFj9*2-8$:-n$&@8$ )58&1&$8-D53*7-F.*:?-F65:$Y-GNej?7*6$+5Y-FRj,3*28*:8-8$9&*3&52-
8-->+CP\+9J!C]+!-.(%/.-+!"2-+"/#+7;11 J)"/&-+^'%7+ Z".-4$/-H
#!
9&-G+R-"'. I"4-G+/+aje ;$7-+.$/*-+,.9+ #$"&/%.$.G+R-"'. Z"*>&'%3/# *6I9!6+2)-'"(RG+ /+aje S"k:-+ ,".2+3.J3''-/2+3.;-/#-'+F%$/2 *%3/2+ adg+F%$/2.e 1W%44-/ F%$/2+*%3/2 add+F%$/2.e J!,G+7&XK 7;11 ,"2$-/2.+W$2)+ -'%.$%/.G /XS=+aje
N*,$7&2$K- ;;\`O$*2-6.*2/$K-^\A
&3.-?,5:&*3&6-*:3.:&3&,->.5->$:$-3:$*3$8-15:(?-35-EA->$$%,-&2-FG"H"D0G;
! " # $ %& ' # $ ( " %) * + , %- # . " /0$ " 1%2 3
AZ5VJ;5(78-7&%$-35-3.*2%KC =77-?*3&$23,->.5-?*:3&6&?*3$8-&2-3.$-,3(84 C =77-,3(84-&29$,3&/*35:, C V(,3&2-U:528&2$, *28-"2/:&8-N(:352-1:5)Q7&2N=q 15:-?:59&8&2/-?:5/:*))&2/-,(??5:3
T&(-TJ-$3-*7\-!"#$%&'(( )*+\-A^;_Y`KI`0E^\ O$*,$ GJ-$3-*7\-,$$")-*.( /0+\-A^;
